Table 1 Patients’ characteristics at ART initiation

Sex

 Female (%)

55 (55.0%)

47 (54.7%)

35 (38.5%)

 Male (%)

45 (45.0%)

39 (45.3)

56 (61.5%)

Age (years)

38.01 ± 7.70

36.19 ± 8.02

35.34 ± 7.00

CD4 + T cell count (cells/μL)

248.64 ± 108.10

288.59 ± 108.86

320.02 ± 123.65

CD4/CD8 ratio

0.31 ± 0.23

0.34 ± 0.21

0.37 ± 0.22

HIV viral load (log₁₀ copies/mL)

5.23 ± 4.86

5.20 ± 4.85

5.21 ± 4.86

BMI (kg/m²)

 < 18.5

19 (19.0%)

5 (5.8%)

9 (9.9%)

 18–24.5

75 (75.0%)

73 (84.9%)

77 (84.6)

 > 24.5

6 (6.0%)

8 (9.3%)

5 (5.5%)

 HBsAg positivity (%)

9 (9.0%)

11 (12.8%)

13 (14.3%)

 Anti-HCV positivity (%)

55 (55.0%)

34 (39.5%)

32 (35.2%)

WHO stage (%)

 I and II

96 (96.0%)

85 (98.8%)

88 (96.7%)

 III and IV

4 (4.0%)

1 (1.2%)

3 (3.3%)

ART regimens (%)

 EFV + TDF + 3TC

62 (62.0%)

59 (68.6%)

58 (63.7%)

 EFV + AZT + 3TC

30 (30.0%)

18 (20.9%)

25 (27.5%)

 NVP + AZT + 3TC

5 (5.0%)

2 (2.3%)

4 (4.4%)

 NVP + TDF + 3TC

1 (1.0%)

2 (2.3%)

0 (0.0%)

 LPV/r + AZT + 3TC

1 (1.0%)

4 (4.7%)

4 (4.7%)

 LPV/r + TDF + 3TC

1 (1.0%)

1 (1.2%)

0 (0.0%)

 Treatment duration (years)

3.93 ± 1.19

3.58 ± 1.25

3.79 ± 1.21

 Leucocyte

6.49 ± 3.73

6.51 ± 2.08

6.50 ± 2.10

 Platelet

170.13 ± 71.57

178.33 ± 62.78

181.10 ± 69.96

 Hemoglobin (g/dL)

139.11 ± 23.53

161.20 ± 219.73

138.84 ± 22.77

 TBil

13.34 ± 9.67

13.85 ± 8.22

15.06 ± 9.70

 ALT

40.16 ± 38.55

37.76 ± 31.76

40.78 ± 47.20

 AST

40.38 ± 33.47

45.84 ± 54.67

40.58 ± 35.39